Recent developments in the chemistry, analysis and control for the manufacture of therapeutic-grade synthetic oligonucleotides

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 6, 2007, Pages 807-818

  Sinha, N D ^a   Michaud, D P ^b  

^a Archemix Corporation   (United States)

^b Avecia Biotechnology Inc   (United States)

Author keywords

Antisense; Aptamers; Capillary electrophoresis; LC MS; LNA; Oligonucleotide mimic; Oligonucleotides; Phosphorothioate; PNA; RNAi

Indexed keywords

OLIGONUCLEOTIDE;

GENE EXPRESSION; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEOTIDE METABOLISM; PURIFICATION; REVIEW; SYNTHESIS;

CHEMISTRY, ANALYTICAL; DRUG COMPOUNDING; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OLIGONUCLEOTIDES; POLYCYCLIC COMPOUNDS;

EID: 36048999201     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 75(1):280-284.
2. Beaucage SL, Caruthers MH: Deoxynucleoside phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett (1981) 22(20):1859-1862.
3. McBride LJ, Caruthers MH: An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. Tetrahedron Lett (1983) 24(3):245-248.
4. Sinha ND, Biernat J, Köster H: β-Cyanoethyl N,N-dialkylamino/N-morpholinomonochlorophosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides. Tetrahedron Lett (1983) 24(52):5843-5846.
5. Sinha ND, Biernat J, McManus J, Köster H: Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,N- dialkylamino-N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res (1984) 12(11):4539-4557.
6. Letsinger RL, Lunsford WB: Synthesis of thymidine oligonucleotides by phosphite triester intermediates. J Am Chem Soc (1976) 98(12):3655-3661.
7. Ogilvie KK, Theriault NY, Seifert JM, Pon RT, Nemez MJ: The chemical synthesis of oligoribonucleotides. IX. A comparison of protecting groups in the dichloridite procedure. Can J Chem (1980) 58(23):2686-2693.
8. Miller PS, McParland KB, Jayaraman K, Ts'o PO: Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry (1981) 20(7):1874-1880.
9. Miller PS, Reddy MP, Murakami A, Blake KR, Lin SB, Agris CH: Solid-phase syntheses of oligodeoxyribonucleoside methylphosphonates. Biochemistry (1986) 25(18):5092-5097.
10. Pless RC, Ts'o PO: Duplex formation of a nonionic oligo(deoxythymidylate) analogue (heptadeoxythymidylyl-(3′-5′)- deoxythymidine heptaethyl ester (d-(Tp(Et))7T)) with poly-(deoxyadenylate). Evaluation of the electrostatic interaction. Biochemistry (1977) 16(6):1239-1250.
11. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S: Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA (1987) 84(21):7706-7710.
12. Stec WJ, Zon G, Egan W: Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. J Am Chem Soc (1984) 106(20):6077-6079.
13. Mungall WS, Kaiser JK: Carbamate analogues of oligonucleotides. J Org Chem (1977) 42(4):703-706.
14. Coull JM, Carlson DV, Weith HL: Synthesis and characterization of a carbamate-linked oligonucleoside. Tetrahedron Lett (1987) 28(7):745-748.
15. Schneider KC, Benner SA: Building blocks for oligonucleotide analogs with dimethylene-sulfide, -sulfoxide, and -sulfone groups replacing phosphodiester linkages. Tetrahedron Lett (1990) 31(3):335- 338.
16. Ogilvie KK, Cormier JF: Synthesis of a thymidine dinucleotide analogue containing an internucleotide silyl linkage. Tetrahedron Lett (1985) 26(35):4159-4162.
17. Cormier JF, Ogilvie KK: Synthesis of hexanucleotide analogues containing diisopropylsilyl internucleotide linkages. Nucleic Acids Res (1988) 16(10):4583-4594.
18. Jones RJ, Lin KY, Milligan JF, Wadwani S, Matteucci MD: Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements: The formacetal and 3′-thioformacetal internucleoside linkages. J Org Chem (1993) 58(11):2983-2991.
19. Veal JM, Gao X, Brown FK: A comparison of DNA oligomer duplexes containing formacetal and phosphodiester linkers using molecular dynamics and quantum mechanics. J Am Chem Soc (1993) 115(16):7139-7145.
20. Azhikina T, Veselovskaya S, Myasnikov V, Potapov V, Ermolayeva O, Sverdlov E: Strings of contiguous modified pentanucleotides with increased DNA-binding affinity can be used for DNA sequencing by primer walking. Proc Natl Acad Sci USA (1993) 90(24):11460-11462.
21. An H, Wang T, Maier MA, Manoharan M, Ross BS, Cook PD: Synthesis of novel 3′-C-methylene thymidine and 5-methyluridine/ cytidine H-phosphonates and phosphonamidites for new backbone modification of oligonucleotides. J Org Chem (2001) 66(8):2789-2801.
22. Soler M, McHutchinson JG, Kwoh TJ, Dorr FA, Pawlotsky JM: Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of HCV IRES, on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther (2004) 9(6):953-968.
23. Shen L, Siwkowski A, Wancewicz EV, Lesnik E, Butler M, Witchell D, Vasquez G, Ross B, Acevedo O, Inamati G, Sasmor H et al: Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev (2003) 13(3):129-142.
24. Seela F, Mersmann K: 7-Deazaguanosine: Phosphoramidite and phosphonate building blocks for solid-phase oligoribonucleotide synthesis. Heterocycles (1992) 34(2):229-236.
25. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM: Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 171(3):1393-1400.
26. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, Barrat FJ: Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol (2005) 174(9):5193-5200.
27. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (1993) 260(5113):1510-1513.
28. Inoue H, Hayase Y, Imura A, Iwai S, Miura K, Ohtsuka E: Synthesis and hybridization studies on two complementary nona(2′-O- methyl) ribonucleotides. Nucleic Acids Res (1987) 15(15):6131-6148.
29. Iribarren AM, Sproat BS, Neuner P, Sulston I, Ryder U, Lamond AI: 2′-O-alkyl oligoribonucleotides as antisense probes. Proc Natl Acad Sci USA (1990) 87(19):7747-7751.
30. Martin P: Stereoselektive synthese von 2-O-(2- methoxyethyl)-ribonucleosiden: Nachbargruppenbeteiligung der methoxyethoxygruppe bei der ribosylierung von heterocyclen. Helv Chim Acta (1996) 79(7):1930-1938.
31. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TGK, Yu RZ, Tami JA, Dorr FA: Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther (2002) 303(3):1334-1343.
32. Siwkowski AM, Madge LA, Koo S, McMillan EL, Monia BP, Pober JS, Baker BF: Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression. Mol Pharmacol (2004) 66(3):572-579.
33. Schmidt S, Niemann A, Krynetskaya NF, Oretskaya TS, Metelev VG, Suchomlinov VV, Shabarova ZA, Cech D: The use of oligonucleotide probes containing 2′-deoxy-2′-fluoronucleosides for regiospecific cleavage of RNA by RNase H from Escherichia coli. Biochim Biophys Acta (1992) 1130(1):41-46.
34. Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD: Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem (1993) 36(7):831-841.
35. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 268(19):14514-14522.
36. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstien F: Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science (1991) 253(5017):314-317.
37. Sigurdsson ST, Eckstein F: Site specific labelling of sugar residues in oligoribonucleotides: Reactions of aliphatic isocyanates with 2′ amino groups. Nucleic Acid Res (1996) 24(16):3129-3133.
38. Teramoto N, Imanishi Y, Ito Y: In vitro selection of ligase ribozymes containing 2′-amino groups. J Bioact Compat Polym (2000) 15(4):297-308.
39. Nielson PE, Egholm M, Berg RH, Buchardt O: Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science (1991) 254(5037):1497-1500. • Details the preparation of oligomers consisting of thymine-linked aminoethylglycyl units; these were observed to recognize complementary sequences in ds DNA demonstrating that specificity was retained.
40. Meltzer PC, Liang AY, Matsudaira P: Peptide nucleic acids: Synthesis of thymine, adenine, guanine, and cytosine nucleobases. J Org Chem (1995) 60(13):4305-4308.
41. Gryaznov SM, Chen JK: Oligodeoxyribonucleotide N3′→ 4P5′ phosphoramidates: Synthesis and hybridization properties. J Am Chem Soc (1994) 116(7):3143-3144.
42. 31P-NMR spectroscopy.
43. Herbert BS, Pongracz K, Shay JW, Gryaznov SM: Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 21(4):638-642.
44. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM: Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene (2005) 24(33):5262-5268. •• The first report describing that lipid modification could enhance the potency of a novel telomerase inhibitor.
45. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acids Drug Dev (1997) 7(3):187-195.
46. Damha MJ, Noronha AM, Wilds CJ, Trempe JF, Denisov A, Pon RT, Gehring K: Properties of arabinonucleic acids (ANA & 20′F-ANA): Implications for the design of antisense therapeutics that invoke RNase H cleavage of RNA. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):429-440.
47. Meldgaard M, Wengel J: Bicyclic nucleosides and conformational restriction of oligonucleotides. Chem Soc Perkin Trans 1 (2000) (21):3539-3554. • Details the synthesis of bicyclic nucleoside monomers; these were demonstrated to improve the binding affinity of oligonucleotide analogs to complementary DNA and RNA.
48. Morita K, Yamate K, Kurakata S, Abe K, Watanabe K, Koizumi M, Imanishi T: Inhibition of VEGF mRNA by 2′-O,4′-C- ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions. Nucleosides Nucleotides Nucleic Acids (2006) 25(4-6):503-521.
49. Yu D, Zhao Q, Kandimalla ER, Agrawal S: Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett (2000) 10(23):2585-2588.
50. Garbesi A, Capobianco ML, Colonna FP, Tondelli L, Arcamone F, Manzini G, Hilbers CW, Aelen JM, Blommers MJ: L-DNAs as potential antimessenger oligonucleotides: A reassessment. Nucleic Acids Res (1993) 21(18):4159-4165.
51. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL: Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther (1998) 286(1):419-428.
52. Crooke ST: Progress in antisense technology. Annu Rev Med (2004) 55:61-95. • Reviews developments in the field of antisense technology, covering basic mechanisms, chemical synthesis and pharmacological and toxicological characteristics of antisense molecules.
53. Kurreck J: Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem (2003) 270(8):1628-1644. •• Provides an overview of developments in the area, focusing on the disadvantages of phosphorothioate DNA oligonucleotides and how second generation oligonucleotides overcome some of these issues.
54. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA: Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther (2002) 303(3):1334-1343.
55. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ: A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol (2005) 16(6):958-965.
56. Cech TR: The chemistry of self-splicing RNA and RNA enzymes. Science (1987) 236(4808):1532-1539.
57. Guerrier-Takada C, Lumelsky N, Altman S: Specific interactions in RNA enzyme-substrate complexes. Science (1989) 246(4937):1578- 1584.
58. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 346(6287):818-822.
59. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249(4968):505-510.
60. Proske D, Blank M, Buhmann R, Resch A: Aptamers-basic research, drug development, and clinical applications. Appl Microbiol Biotechnol (2005) 69(4):367-374. •• Provides an overview of developments in aptamer research, considering their value as tools for diagnostics, purification processes, target validation, drug discovery and as therapeutic agents.
61. Bock C, Griffin LC, Latham JA, Vermaas EH, Toole JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355(6360):564-566. • Describes the isolation of single-stranded DNA thrombin aptamers. Several aptamers were observed to inhibit thrombin-catalyzed fibrin-clot formation in vitro at nanomolar concentrations.
62. 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem (1998) 273(32):20556-20567.
63. Klussman S, Nolte A, Bald R, Erdmann VA, Furste JP: Mirror-image RNA that binds D-adenosine. Nature Biotechnol (1996) 14(9):1112-1115.
64. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374(6522):546-549. • Describes in vitro and in vivo studies demonstrating that synthetic oligodeoxynucleotides containing unmethylated CpG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin.
65. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 164(2):944-953. •• An optimal human CpG motif is identified and a phosphodiester oligonucleotide containing this motif is demonstrated to strongly stimulate CD86, CD40, CD54 and MHC class II expression, IL-6 synthesis and proliferation of primary human B cells.
66. Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H: CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 17(21):6230-6240.
67. Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z: CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J (2002) 16(3):274-282.
68. Fanucchi MV, Schelegle ES, Baker GL, Evans MJ, McDonald RJ, Gershwin LJ, Raz E, Hyde DM, Plopper CG, Miller LA: Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med (2004) 170(11):1153-1157.
69. Roberts TL, Sweet MJ, Hume DA, Stacey KJ: Cutting edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol (2005) 174(2):605-608.
70. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA (1995) 92(13):5855-5859.
71. Mann MJ, Dzau VJ: Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest (2000) 106(9):1071-1075. • Describes the transcription factor decoy approach, which can enable specific gene activation or repression.
72. Liu WM, Scott KA, Shahin S, Propper DJ: The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur J Biochem (2004) 271(13):2773-2781.
73. Kalinowski M, Viehofer K, Hamann C, Barry JJ, Kleb B, Klose KJ, Wagner HJ, Alfke H: Local administration of NF-κB decoy oligonucleotides to prevent restenosis after balloon angioplasty: An experimental study in New Zealand white rabbits. CardioVasc Intervent Radiol (2005) 28(3):331-337.
74. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811.
75. Elbashir SM, Harborth J, Weber K, Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 26(2):199-213. •• Provides protocols for siRNA-mediated knockdown of mammalian gene expression.
76. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 438(7068):685-689.
77. Devi GR: siRNA-based approaches in cancer therapy. Cancer Gene Ther (2006) 13(9):819-829. • Summarizes a decade of advances in post-transcriptional gene silencing, comparing RNAi approaches with other oligonucleotide-based strategies.
78. Iyer RP, Egan W, Regan JB, Beaucage SL: 3H-1,2- Benzodithiol-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J Am Chem Soc (1990) 112(3):1253-1254.
79. Tang JY, Han Y, Tang JX, Zhang Z: Large-scale synthesis of oligonucleotide phosphorothioates using 3-amino-1,2,4-dithiazole-5-thione as an efficient sulfur-transfer reagent. Org Process Res Dev (2000) 4(3):194-198.
80. Cheruvallath ZS, Carty RL, Moore MN, Capaldi DC, Krotz AH, Wheeler PD, Turney BJ, Craig SR, Gaus HJ, Scozzari AN, Cole DL et al: Synthesis of antisense oligonucleotides: Replacement of 3H-1,2-benzodithiol- 3-one 1,1-dioxide (Beaucage reagent) with phenylacetyl disulfide (PADS) as efficient sulfurization reagent: From bench to bulk manufacture of active pharmaceutical ingredient. Org Process Res Dev (2000) 4(3):199-204.
81. Krotz AH, Gorman D, Mataruse P, Foster C, Godbout JD, Coffin CC, Scozzari AN: Phosphorothioate oligonucleotides with low phosphate diester content: Greater than 99.9% sulfurization efficiency with "aged" solutions of phenylacetyl disulfide (PADS). Org Process Res Dev (2004) 8(6):852-858.
82. Vargeese C, Carter J, Yegge J, Krivjansky S, Settle A, Kropp E, Peterson K, Pieken W: Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis. Nucleic Acids Res (1998) 26(4):1046-1050.
83. Krotz AH, Carty RL, Scozzari AN, Cole DL, Ravikumar VT: Large-scale synthesis of antisense oligonucleotides without chlorinated solvents. Org Process Res Dev (2000) 4(3):190-193.
84. Pitsch S, Weiss PA, Jenny L, Stutz A, Wu X: Reliable chemical synthesis of oligoribonucleotides (RNA) with 2′-O- [(triisopropylsilyl) oxy]methyl(2-O-tom)-protected phosphoramidites. Helv Chim Acta (2001) 84(12):3773-3795.
85. Scringe SA, Wincott FE, Caruthers MH: Novel RNA synthesis method using 5′-O-silyl-2′-O-orthoester protecting groups. J Am Chem Soc (1998) 120(45):11820-11821.
86. Ohgi T, Masutomi Y, Ishiyama K, Kitagawa H, Shiba Y, Yano J: A new RNA synthetic method with a 2′-O-(2-cyanoethoxymethyl) protecting group. Org Lett (2006) 7(16):3477-3480.
87. Sinha ND: Large-scale oligonucleotide synthesis using the solidphase approach. In: Protocols for Oligonucleotides and Analogs: Synthesis and Properties. Methods in Molecular Biology Series Volume 20. Agrawal S (Ed), Humana Press, Totowa, NJ, USA (1993):437-464.
88. Padmapriya AA, Tang J, Agrawal S: Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res Dev (1994) 4(3):185-199.
89. Fry S, Sinha ND: Improvements in the large scale oligonucleotide (DNA/RNA) synthesis on solid supports. In: Innovation and Perspectives in Solid Phase Synthesis: Peptides, Proteins and Nucleic Acids. Proceedings of the 3rd International Symposium. Epton R (Ed), Mayflower Worldwide Ltd, Oxford, UK (1994):135-144.
90. Kumar RK, Olsen P, Ravikumar VT: An alternative advantageous protocol for efficient synthesis of phosphorothioate oligonucleotides utilizing phenylacetyl disulfide (PADS). Nucleosides Nucleotides Nucleic Acids (2007) 26(2):181-188.
91. Deshmukh RR, Miller JE, De Leon P, Leitch WE 2nd, Cole DL, Sangvi YS: Process development for purification of therapeutic antisense oligonucleotides by anion-exchange chromatography. Org Process Res Dev (2000) 4(3):205-213.
92. Cohen AS, Terabe S, Smith JA, Karger BL: High-performance capillary electrophoretic separation of bases, nucleosides, and oligonucleotides: Retention manipulation via micellar solutions and metal additives. Anal Chem (1987) 59(7):1021-1027.
93. Cohen AS, Najarian DR, Paulus A, Guttman A, Smith JA, Karger BL: Rapid separation and purification of oligonucleotides by high-performance capillary gel electrophoresis. Proc Natl Acad Sci USA (1988) 85(24):9660-9663.
94. Guttman A, Cooke N: Capillary gel affinity electrophoresis of DNA fragments. Anal Chem (1991) 63(18):2038-2042.
95. Chen JW, Cohen AS, Karger BL: Identification of DNA molecules by pre-column hybridization using capillary electrophoresis. J Chromatogr A (1991) 559(1-2):295-305.
96. Drager RR, Regnier FE: High-performance anion-exchange chromatography of oligonucleotides. Anal Biochem (1985) 145(1):47-56.
97. Agrawal S, Tang JY, Brown DM: Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. J Chromatogr A (1990) 509(2):396-399.
98. Bergot BJ, Egan W: Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography. J Chromatogr A (1992) 599(1-2):35-42. • Describes a method for separating synthetic deoxynucleotide phosphorothioates from their oxygenated defect species using 'soft base' anionic eluents.
99. Thayer JR, McCormick RM, Avdalovic N: High-resolution nucleic acid separations by high-performance liquid chromatography. Methods Enzymol (1996) 271:147-174.
100. Hill TL, Mayhew JW: Convenient purification of tritylated and detritylated oligonucleotides up to 100-mer. J Chromatogr A (1990) 512:415-431.
101. Makino K, Ozaki H, Matsumoto T, Imaishi H, Takeuchi T, Fukui T: Reversed-phase ion-pair chromatography of oligodeoxyribonucleotides. J Chromatogr A (1987) 400:271-277.
102. Huber CG, Oefner PJ, Bonn GK: High-performance liquid chromatographic separation of detritylated oligonucleotides on highly cross-linked poly-(styrene-divinylbenzene) particles. J Chromatogr A (1992) 599(1-2):113-118.
103. Apffel A, Chakel JA, Fischer S, Lichtenwalter K, Hancock WS: New procedure for the use of high-performance liquid chromatography-electrospray ionization mass spectrometry for the analysis of nucleotides and oligonucleotides. J Chromatogr A (1997) 777(1):3-21. • Describes an analytical method that combines HPLC and ESI MS for the analysis of nucleotides and oligonucleotides; a novel additive, 1,1,1,3,3,3-hexafluoro- 2-isopropanol, in the HPLC mobile phase produces good HPLC separation.
104. Gilar M: Analysis and purification of synthetic oligonucleotides by reversed-phase high-performance liquid chromatography with photodiode array and mass spectrometry detection. Anal Biochem (2001) 298(2):196- 206. • Details a RP-HPLC method utilizing volatile ion-pairing mobile phases that could be used to purify single injections of up to 90 nmol of oligonucleotides.
105. Spengler B, Cotter RJ: Ultraviolet laser desorption/ionization mass spectrometry of proteins above 100,000 Daltons by pulsed ion extraction time-of-flight analysis. Anal Chem (1990) 62(8):793-796.
106. Tang NI, Taranenko N, Allman SL, Chen CH, Chang LY, Jacobson KB: Picolinic acid as a matrix for laser mass spectrometry of nucleic acids and proteins. Rapid Commun Mass Spectrom (1994) 8(9):673-677.
107. Pieles U, Zürcher W, Schär M, Moser HE: Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: A powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Res (1993) 21(14):3191-3196.
108. Juhasz P, Roskey MT, Smirnov IP, Haff LA, Vestal ML, Martin SA: Applications of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry to oligonucleotide analysis. Anal Chem (1996) 68(6):941-946.
109. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM: Electrospray ionization for mass spectrometry of large biomolecules. Science (1989) 246(4926):64-71. • Provides an overview of ESI for the production of intact ions from large and complex biopolymers including oligonucleotides.
110. Capaldi DC, Gaus H, Krotz AH, Arnold J, Carty RL, Moore MN, Scozzari AN, Lowery K, Cole DL, Ravikumar VT: Synthesis of high-quality antisense drugs. Addition of acrylonitrile to phosphorothioate oligonucleotides: Adduct characterization and avoidance. Org Proc Res Dev (2003) 7(6):832-838.
111. Gaus H, Olsen P, Sooy KV, Rentel C, Turney B, Walker KL, McArdle JV, Capaldi DC: Trichloroacetaldehyde modified oligonucleotides. Bioorg Med Chem Lett (2005) 15(18):4118-4124.
112. Chaix C, Molko D, Téoule R: The use of labile base protecting groups in oligoribonucleotide synthesis. Tetrahedron Lett (1989) 30(1):71-74. • Details the observation of an [M+42] impurity by MALDI-TOF MS and LC-MS ESI in oligonucleotide syntheses using acetic anhydride as a capping agent. This impurity could be eliminated with the use of isobutyric anhydride.
113. Kurata C, Bradley K, Gaus H, Luu N, Cedillo I, Ravikumar VT, Van Sooy K, McArdle JV, Capaldi DC: Characterization of high molecular weight impurities in synthetic phosphorothioate oligonucleotides. Bioorg Med Chem Lett (2006) 16(3):607-614.
114. AVECIA BIOTECHNOLOGY INC (Sinha ND, Zedalis WE, Miranda GK): Activators for oligonucleotide synthesis. WO-2003004512 (2003).
115. AVECIA BIOTECHNOLOGY INC (Zhang G, Tang JY): Detritylation solvents for nucleic acid synthesis. US-06538128 (2003).
116. ISIS PHARMACEUTICALS INC (Guzaev AP, Manoharan M): Universal support media for synthesis of oligomeric compounds. US-06653468 (2003).